Key Takeaways
- Shares of BIAF jumped more than 55% Tuesday following news the company is expanding CyPath Lung’s application to include lung cancer recurrence monitoring
- BioAffinity is investigating whether CyPath Lung can detect cancer recurrence in patients who have undergone curative-intent therapy
- More than 680,000 Americans were living with a previous lung cancer diagnosis as of January 1, 2025
- Daily trading volume surged past 17 million shares, significantly exceeding the 5.91 million three-month average
- Spark AI analyst assigns BIAF an Underperform rating with a $5.50 target, highlighting cash concerns and falling revenue
Shares of BioAffinity Technologies rocketed higher by more than 55% during Tuesday’s session after the medical diagnostics company released news regarding an expanded application for its CyPath Lung testing platform targeting lung cancer survivors.
bioAffinity Technologies, Inc., BIAF
The shares opened Tuesday’s session with strong momentum, having already gained 65.57% during premarket hours. This came after a 6.37% decline in the previous trading day. Despite Tuesday’s rally, BIAF remains down 74.24% year-to-date and has plummeted 95.72% over the trailing twelve months.
The company revealed it is investigating CyPath Lung’s potential as a surveillance tool for monitoring cancer recurrence in individuals who have completed treatment with curative intent.
Data from the American Cancer Society indicates that over 680,000 people in the United States were living with a history of lung cancer diagnosis as of the beginning of 2025. The National Cancer Institute projects approximately 230,000 new diagnoses in 2026.
When patients complete their treatment regimen, the appearance of a new pulmonary nodule on imaging studies can create significant diagnostic uncertainty. While CT scans can identify nodules, they often cannot definitively distinguish between cancerous tissue, new tumor development, or benign post-treatment changes like scarring or inflammatory processes.
CyPath Lung delivers a straightforward binary assessment: either “unlikely” or “likely” malignancy. This classification system could assist physicians in determining which patients require additional workup versus those who can remain on standard surveillance protocols.
Clinical research indicates that non-small cell lung cancer recurrence rates range from 20% to 55%, varying based on disease stage and therapeutic approach. The American Society of Clinical Oncology guidelines recommend surveillance imaging at six-month intervals for the first two years following curative-intent therapy for stage I through III NSCLC.
Performance Data for CyPath Lung
The diagnostic test employs flow cytometry combined with proprietary artificial intelligence to evaluate cellular populations within patient sputum samples. Published clinical trial results demonstrated 92% sensitivity, 87% specificity, 88% overall accuracy, and a 99% negative predictive value for identifying early-stage lung cancer in high-risk populations.
According to BioAffinity, three years of real-world commercial deployment have demonstrated the test’s utility in helping physicians evaluate malignancy risk and inform patient management decisions, including situations where imaging findings and predictive modeling yielded inconsistent information.
Company CEO Maria Zannes stated that post-treatment surveillance “has the potential to lead to earlier intervention” and could complement existing early detection approaches.
Dr. Vijay Gunuganti, an oncologist with Texas Oncology, noted that CyPath Lung “can provide additional information without immediately subjecting the patient to an invasive procedure.”
Dr. Gordon Downie, Chief Medical Officer and PhD, emphasized that completing treatment is “not the end of cancer care,” underscoring the increasing significance of survivorship surveillance programs.
Trading Activity and Wall Street Perspective
Tuesday’s trading volume exceeded 17 million shares, substantially above the three-month daily average of approximately 5.91 million. Such dramatic volume increases typically indicate significant retail investor engagement in response to material news.
CyPath Lung operates as a Laboratory Developed Test and has not received regulatory clearance as an independent diagnostic device. The clinical performance metrics referenced pertain to detection applications and have not undergone separate validation for post-treatment surveillance scenarios.
Spark’s AI analyst maintains an Underperform rating on BIAF with a $5.50 price objective, pointing to severe cash burn rates, declining revenue trends, and potential Nasdaq delisting concerns as primary risk factors.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
